Literature DB >> 2144300

Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

N Harata1, T Sasaki, H Osaki, T Saito, S Shibata, T Muryoi, O Takai, K Yoshinaga.   

Abstract

-81 and NE-1 idiotypes (Id) of human nephritogenic anti-DNA antibodies are interspecies Id expressed also in NZB/W F1 mice. We tried to manipulate the synthesis of spontaneously occurring anti-DNA antibody using monoclonal anti-Id antibodies (D1E2 and 1F5) conjugated with a cytotoxic agent, neocarzinostatin (NCS). In vivo administration of anti-Id antibodies conjugated with NCS brought about an improvement in the survival rate of female NZB/W F1 mice. It also caused a retardation of development of lupus nephritis and decreased the numbers of anti-DNA-producing cells. The suppression of anti-DNA antibody synthesis was specific and Id-mediated. The results indicate that the use of a limited number of anti-Id antibodies in combination with a cytotoxic agent may be applicable therapeutically to autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144300      PMCID: PMC296791          DOI: 10.1172/JCI114773

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  The genetic contribution of the NZB mouse to the renal disease of the NZB x NZW hybrid.

Authors:  J G Knight; D D Adams; H D Purves
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

2.  Internal images of major histocompatibility complex antigens on T-cell receptors and their role in the generation of the T-helper cell repertoire.

Authors:  G K Sim; A A Augustin
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

3.  Establishment of human monoclonal anti-DNA antibody producing cell lines.

Authors:  T Sasaki; F Endo; M Mikami; Y Sekiguchi; K Tada; Y Ono; N Ishida; K Yoshinaga
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

4.  Biological activity of the antitumor protein neocarzinostatin coupled to a monoclonal antibody by N-succinimidyl 3-(2-pyridyldithio)-propionate.

Authors:  G Jung; W Köhnlein; G Lüders
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

5.  Quantitative immunology of immune hemolytic anemia: II. The relationship of cell-bound antibody to hemolysis and the effect of treatment.

Authors:  W F Rosse
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

6.  Suppression of in vitro monoclonal human rheumatoid factor synthesis by antiidiotypic antibody. Target cells and molecular requirements.

Authors:  W J Koopman; R E Schrohenloher; J C Barton; E C Greenleaf
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

7.  Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA.

Authors:  B H Hahn; F M Ebling
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

8.  Induction of autoantibodies to thyroglobulin by anti-idiotypic antibodies.

Authors:  M Zanetti; J Rogers; D H Katz
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

9.  Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using anti-idiotypic antibodies coupled to the A chain of ricin.

Authors:  R M DeShambo; K A Krolick
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

10.  Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients.

Authors:  D S Dwyer; R J Bradley; C K Urquhart; J F Kearney
Journal:  Nature       Date:  1983 Feb 17-23       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.